Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2636

We are living in a world that is global and exponential. Technology is taking things that used to be scarce and making them abundant—and these forces are reshaping the fields of medicine and healthcare in completely novel ways.

Opening this year’s Exponential Medicine conference in San Diego, Daniel Kraft, the curator of the conference, and faculty chair of Medicine and Neuroscience at Singularity University, took the audience on a whirlwind tour of the latest developments in healthcare and medicine.

watch-the-live-stream

Read more

Lung cancer treatment is moving beyond chemotherapy, with Merck & Co. setting the pace in a new category of therapies that harness the body’s immune system to fight tumors.

The U.S. drugmaker’s drug Keytruda reduced the risk of death or cancer progression by 50 percent, Merck said, unveiling details of a crucial study at a meeting of the European Society for Medical Oncology. The medicine gave patients an average of 10.3 months before their cancer progressed, compared with six months on chemotherapy. Unlike competitor Bristol-Myers Squibb Co., whose similar drug Opdivo failed in an advanced trial and caused its stock to plunge, Merck selected patients who harbored high levels of a protein thought to predict how well the immune-system drugs will work.

The results give Merck a head start — and not just on Bristol-Myers. Roche Holding AG and AstraZeneca Plc are also in the race for the best new immune therapy against lung tumors, the most common cancer in the world. Doctors will probably start testing patients soon after diagnosis to see whether they’re suited to treatment with Keytruda and can forgo the many side effects of chemotherapy, said Stefan Zimmermann, a chief oncologist at the Cantonal Hospital of Fribourg, Switzerland.

Read more

Last week the U.S. corporation Monsanto, which holds a leading position in the global market of genetically modified organisms (GMOs), reached a licensing agreement with the Broad Institute, Cambridge, USA, on the commercial use of the innovative genome-editing technology CRISPR/Cas9 for agriculture applications. This news has led some experts to believe that Monsanto will now completely switch from producing ‘traditional’ GMOs to ‘genetically edited’ organisms, which are supposedly ‘safer and practically identical’ to their natural alternatives.

Let’s have a closer look at this technology which makes GMO supporters feel so enthusiastic and has been positioned by them as the universal panacea solving all of mankind’s problems. We will also delve deeper into some of the darker aspects of CRISPR/Cas9; the points that biotechnology lobbyists prefer not to discuss.

crispr

Read more

Follow along with the Exponential Medicine 2016 livestream, presented by Guidewell. Join Singularity University as we explore the convergence of health and technology to catalyze the future of medicine.

Join us on Twitter @ExponentialMed and with #xmed.

Connect with Singularity University:
Website: http://singularityu.org

Singularity HUB: http://singularityhub.com

Continue reading “Singularity University Live Stream of Exponential Medicine 2016” | >

Neural Nanonics here we come: “Could lead to future autonomous, fully implantable neuroprosthetic devices”

Memristor chip (credit: University of Southampton)

A bio-inspired electronic device called a memristor could allow for real-time processing of neuronal signals (spiking events), new research led by the University of Southampton has demonstrated.

The research could lead to using multi-electrode array implants for detecting spikes in the brain’s electrical signals from more than 1,000 recording channels to help treat neurological conditions, without requiring expensive, high-bandwidth, bulky systems for processing data. The research could lead to future autonomous, fully implantable neuroprosthetic devices.

Continue reading “Synapse-like memristor-based electronic device detects brain spikes in real time” | >

A great new biomarker for senescent cells is available and will allow researchers to more measure levels of aged cells easier and faster. Great news for gerontologists wishing to demonstrate changes to aged cell populations after therapies.

Scientists have discovered a new way to look for ageing cells across a wide range of biological materials; the new method will boost understanding of cellular development and ageing as well as the causes of diverse diseases.

Frustrated by the limitations of commercially available biomarkers — researchers led by The University of Manchester’s Professor Paul Townsend and senior author of the resulting paper, and honorary professor at Manchester, Professor Vassilis Gorgoulis, have developed a universally applicable method to assess senescence across biomedicine, from cancer research to gerontology.

Cellular senescence is a fundamental biological process involved in every day embryonic and adult life, both good – for normal human development – and, more importantly to researchers, dangerous by triggering disease conditions. Up to now available senescence detecting biomarkers have very limited and burdensome application. Therefore, a more effective, precise and easy-to-use biomarker would have considerable benefits for research and clinical practice.

Continue reading “New method to detect ageing cells – and aid rejuvenation therapies — developed” | >

In Brief.

  • Every year, more than 795,000 people in the United States have a stroke.
  • A team of scientists has discovered a common mechanism chain leading to brain cell death which involves proteins eating away at a cell’s DNA.

A team of scientists has discovered that, despite having varied causes and symptoms, most brain diseases all share a common mechanism chain leading to brain cell death. The process, aptly named parthanatos after an enzyme called PARP and the Greek god of death, involves proteins eating away at the cell’s DNA.

Read more

Rapamycin could lead to the development of drugs to delay some aspects of aging in particular the immune systems decline with age.

Nearly a decade of research showing that Rapamycin makes mice live up to 60% longer, scientists are trying it out as an anti-aging drug in dogs and humans.

Researchers at the University of Washington’s Dog Aging Project gave rapamycin to 16 dogs and imaged their hearts.

“It started to function better. It started to look like a more youthful heart,” said Matt Kaeberlein, co-director of the Dog Aging Project, who has presented this research at conferences but hasn’t yet published it.

Continue reading “Side Effects of Antiaging drug Rapamycin can be managed with lower doses and appears to improve the immune system, restore vitality and delay heart disease and dementia” | >